Key Points
- Insider sale: Kevin McCulloch sold 15,000 Xeris Biopharma shares at an average of $9.41, generating $141,150. The transaction was made under a pre-arranged Rule 10b5-1 plan, leaving him with 1,599,208 shares.
- Financial and stock performance: XERS opened at $9.08, down 1.8%, with a 12-month range of $5.25 to $11.33. The company missed quarterly EPS expectations but exceeded revenue estimates.
- Analyst outlook: Analysts have an average “Hold” rating and a $12.80 price target, although Leerink Partners and Barclays recently raised their targets to $16 and $12, respectively.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $9.41, for a total value of $47,050.00. Following the completion of the sale, the insider owned 1,351,053 shares of the company's stock, valued at approximately $12,713,408.73. The trade was a 0.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Steven Pieper also recently made the following trade(s):
- On Tuesday, September 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total value of $42,500.00.
- On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total value of $42,500.00.
- On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.52, for a total transaction of $235,152.00.
- On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $147,900.00.
Xeris Biopharma Stock Performance
NASDAQ:XERS opened at $9.08 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a twelve month low of $5.25 and a twelve month high of $11.33. The company has a fifty day moving average of $8.46 and a 200-day moving average of $7.30. The firm has a market capitalization of $1.66 billion, a P/E ratio of -82.55 and a beta of 0.53.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of $0.01 by ($0.19). The company had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. As a group, sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.
Institutional Trading of Xeris Biopharma
Several institutional investors and hedge funds have recently modified their holdings of XERS. Walleye Capital LLC purchased a new position in shares of Xeris Biopharma during the second quarter valued at approximately $4,841,000. Canada Pension Plan Investment Board bought a new stake in Xeris Biopharma during the second quarter worth $1,736,000. Legal & General Group Plc purchased a new stake in Xeris Biopharma in the 2nd quarter valued at $15,941,000. Rice Hall James & Associates LLC purchased a new stake in Xeris Biopharma in the 1st quarter valued at $1,456,000. Finally, Janus Henderson Group PLC raised its position in Xeris Biopharma by 322.8% in the 1st quarter. Janus Henderson Group PLC now owns 295,489 shares of the company's stock valued at $1,713,000 after buying an additional 225,602 shares during the last quarter. 42.75% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
XERS has been the topic of a number of research reports. Weiss Ratings downgraded Xeris Biopharma from a "hold (c-)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Leerink Partners increased their target price on Xeris Biopharma from $12.00 to $16.00 and gave the stock an "outperform" rating in a report on Thursday, September 10th. Wall Street Zen upgraded shares of Xeris Biopharma from a "hold" rating to a "buy" rating in a research note on Saturday, September 19th. Finally, Barclays upped their price objective on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an "overweight" rating in a report on Thursday, August 20th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $12.80.
Read Our Latest Research Report on Xeris Biopharma
Xeris Biopharma Company Profile
(
Get Free Report)
Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.
Xeris' commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing's syndrome.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
